This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| ATP-4/10 | |
|---|---|
| Name | ATP-4/10 |
| Caption | Structural schematic |
ATP-4/10 is a synthetic analogue described in experimental literature as a modified adenosine triphosphate derivative studied for biochemical signaling, enzymology, and translational research. It has been investigated across laboratories affiliated with institutions such as Massachusetts Institute of Technology, Harvard University, Stanford University, University of Oxford and Max Planck Society, and discussed at meetings including the Gordon Research Conferences and Cold Spring Harbor Laboratory symposia. Publications in journals like Nature, Science, Cell, Proceedings of the National Academy of Sciences, and The Lancet have compared its properties to canonical nucleotides.
ATP-4/10 is positioned in the literature as an engineered nucleotide analogue evaluated by researchers from centers such as National Institutes of Health, European Molecular Biology Laboratory, Johns Hopkins University, University of Cambridge, and University of California, Berkeley. Reviews and articles by authors affiliated with Howard Hughes Medical Institute groups and contributors to Nature Reviews Molecular Cell Biology outline its relevance alongside molecules studied by teams at Cold Spring Harbor Laboratory, Karolinska Institutet, Weizmann Institute of Science, and Imperial College London.
Chemically, ATP-4/10 is described as a modified adenosine core bearing phosphate moieties altered at positions analogous to those characterized in structural studies by groups at Riken, Swiss Federal Institute of Technology Zurich, The Scripps Research Institute, University of Tokyo, and Korea Advanced Institute of Science and Technology. Structural elucidation has drawn on techniques used by laboratories publishing in Nature Communications and Journal of the American Chemical Society, employing cryo-electron microscopy advances championed at European Synchrotron Radiation Facility and X-ray crystallography workflows used at Diamond Light Source and Argonne National Laboratory. Computational modeling efforts referenced by teams at Lawrence Berkeley National Laboratory and Los Alamos National Laboratory applied force fields and density functional theory methods common in studies from California Institute of Technology.
Reports propose that ATP-4/10 interacts with nucleotide-binding sites in enzymes and receptors studied across systems by investigators at Yale University, Columbia University, Duke University, and University of Pennsylvania. Mechanistic frameworks build on paradigms established in seminal work from Max Planck Institute for Biophysical Chemistry and experiments appearing in EMBO Journal and Molecular Cell. Comparisons to substrates characterized by researchers at Wistar Institute and Cold Spring Harbor Laboratory indicate modulation of catalytic cycles comparable to analogues evaluated by teams at Broad Institute and St. Jude Children's Research Hospital.
In cell-based and organismal assays run by groups at University of California, San Francisco, Vanderbilt University, McGill University, University of Toronto, and University of Melbourne, ATP-4/10 has been probed for effects on pathways previously mapped by scientists at Howard Hughes Medical Institute, Fred Hutchinson Cancer Center, Salk Institute, and European Molecular Biology Laboratory. Physiological readouts referenced in comparative studies published by authors from Mount Sinai Hospital, Cleveland Clinic, Karolinska Institutet, and Johns Hopkins University situate ATP-4/10 within signaling contexts analogous to those explored in work from Rutherford Appleton Laboratory and Institute Pasteur.
ATP-4/10 has been used as a tool compound in translational programs associated with consortia including researchers from National Cancer Institute, Biotechnology and Biological Sciences Research Council, Wellcome Trust, Medical Research Council (United Kingdom), and industry partners such as Pfizer, Roche, Novartis, GlaxoSmithKline, and Bayer. Applications described in preclinical studies span assays common to laboratories at Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, and Ludwig Institute for Cancer Research and have been discussed in context with therapeutic strategies investigated at European Organization for Research and Treatment of Cancer and U.S. Food and Drug Administration advisory panels.
Safety evaluations have been conducted in settings affiliated with World Health Organization, Centers for Disease Control and Prevention, European Medicines Agency, and institutional animal facilities at National Institutes of Health and Karolinska Institutet. Toxicological analyses use methodologies established by toxicology groups at University of California, Davis, Ohio State University, University of Michigan, and Johns Hopkins Bloomberg School of Public Health, and follow reporting standards found in articles from Toxicological Sciences and Environmental Health Perspectives.
The conceptual origins of ATP-4/10 draw on decades of nucleotide chemistry pioneered by researchers at Cambridge University, University of Oxford, ETH Zurich, University of Chicago, and Princeton University. Key experimental milestones parallel advances reported in conferences at Gordon Research Conferences, EMBO Workshops, and symposia held by American Society for Biochemistry and Molecular Biology and American Chemical Society. Early synthetic and mechanistic work was carried out in laboratories linked to Scripps Research Institute, Max Planck Society, Riken, and Weizmann Institute of Science, with subsequent dissemination through publications in Nature, Science, and Cell.
Category:Nucleotides